新型抗精神病药SEP-363856  

A novel antipsychotic drug,SEP-363856

作　　者：唐金蕾 司淑萍 翟金国[1] 赵靖平[3] 林烁 TANG Jin-lei;SI Shu-ping;ZHAI Jin-guo;ZHAO Jing-ping;LIN Shuo(School of Mental Health of Jining Medical University,Jining 272067,China;Jining Mental Hospital,Jining 272051,China;Mental Health Institute of The Second Xiangya Hospital,Key Laboratory of Psychiatry and Mental Health of Hunan Province,Central South University,Changsha 410011,China)

机构地区：[1]济宁医学院精神卫生学院,济宁272067 [2]济宁市精神病防治院,济宁272051 [3]中南大学湘雅二医院精神卫生研究所,精神病学与精神卫生学湖南省重点实验室,长沙410011

出　　处：《中国新药杂志》2021年第8期685-689,共5页Chinese Journal of New Drugs

基　　金：山东省自然科学基金项目(ZR2017LH036);山东省医药卫生科技发展计划项目(2015WS0417,2013WS0329);山东省高等学校科技计划项目(J14LK56);济宁医学院教师发展基金(JY2017JS007);济宁医学院大学生科研项目(JYXS2017KJ012)。

摘　　要：SEP-363856是一种新型抗精神病药,确切的作用机制未明,目前研究认为,该药与以往的抗精神病药作用机制不同,它不是通过拮抗多巴胺D_(2)受体,而是通过激活5-羟色胺1A(5-HT_(1A))受体以及痕量胺相关受体1(TAAR1)而发挥药理作用。最近SEP-363856获得美国FDA授予的突破性疗法认定,用于治疗成人精神分裂症。本文对突破性疗法、SEP-363856的药理作用机制、药动学、药物相互作用、临床应用、安全性和耐受性等相关文献进行综述。SEP-363856 is a novel antipsychotic drug,the exact mechanism of action of which is not clear.At present,it is believed that the mechanism of action of sep-363856 is different from that of previous antipsychotic drugs,it does not play a pharmacological role by antagonizing dopamine D_(2) receptor,but by activating 5-hydroxytryptamine 1A(5-HT_(1A))receptor and trace amine-associated receptor 1(TAAR1).Recently,SEP-363856 has received breakthrough therapy designation of the US Food and Drug Administration for the treatment of adult patients with schizophrenia.In this paper,breakthrough therapy designation,the pharmacological mechanism,pharmacokinetics,drug-drug interaction,clinical application,safety and tolerance of SEP-363856 are reviewed.

关 键 词：SEP-363856 抗精神病药 精神分裂症 临床应用 耐受性 

分 类 号：R971[医药卫生—药品]